NASDAQ:SOLYSoliton Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Soliton Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.22 +0.33 (+4.79 %) (As of 08/14/2020 04:00 PM ET) Add Compare Share Today's Range$6.80Now: $7.22▼$7.3050-Day Range$6.44MA: $7.64▼$11.8552-Week Range$6.25Now: $7.22▼$15.50Volume224,079 shsAverage Volume241,008 shsMarket Capitalization$152.99 millionP/E RatioN/ADividend YieldN/ABeta-0.01 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Soliton, Inc., an early stage medical device company, focuses on developing and commercializing products using a proprietary rapid acoustic pulse technology platform. It offers a device for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSoliton has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.67, Soliton has a potential upside of 130.8% from its current price of $7.22.Amount of Analyst CoverageSoliton has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesSoliton has received 75 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSoliton has received 60 “underperform” votes. (Add your “underperform” vote.)Community SentimentSoliton has received 55.56% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Soliton and other stocks. Vote “Outperform” if you believe SOLY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SOLY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSoliton does not currently pay a dividend.Dividend GrowthSoliton does not have a long track record of dividend growth. Previous Next 3.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soliton insiders have bought more of their company's stock than they have sold. Specifically, they have bought $999,992.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 11.30% of the stock of Soliton is held by insiders.Percentage Held by InstitutionsOnly 11.30% of the stock of Soliton is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Soliton are expected to decrease in the coming year, from ($0.77) to ($0.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soliton is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soliton is -7.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoliton has a P/B Ratio of 11.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.86 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SOLY Previous Symbol CUSIPN/A CIKN/A Webwww.soliton.com Phone844-705-4866Debt Debt-to-Equity RatioN/A Current Ratio4.68 Quick Ratio4.68Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book11.84Profitability EPS (Most Recent Fiscal Year)($1.00) Net Income$-13,750,000.00 Net MarginsN/A Return on Equity-154.06% Return on Assets-121.97%Miscellaneous Employees7 Outstanding Shares21,190,000Market Cap$152.99 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $7.22 +0.33 (+4.79 %) (As of 08/14/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SOLY News and Ratings via Email Sign-up to receive the latest news and ratings for SOLY and its competitors with MarketBeat's FREE daily newsletter. Soliton (NASDAQ:SOLY) Frequently Asked Questions How has Soliton's stock price been impacted by Coronavirus? Soliton's stock was trading at $10.66 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, SOLY shares have decreased by 32.3% and is now trading at $7.22. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Soliton? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Soliton in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Soliton. When is Soliton's next earnings date? Soliton is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Soliton. How were Soliton's earnings last quarter? Soliton Inc (NASDAQ:SOLY) released its earnings results on Tuesday, August, 11th. The company reported ($0.19) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.19). View Soliton's earnings history. What price target have analysts set for SOLY? 3 Wall Street analysts have issued twelve-month target prices for Soliton's shares. Their forecasts range from $12.00 to $22.00. On average, they anticipate Soliton's share price to reach $16.67 in the next year. This suggests a possible upside of 130.8% from the stock's current price. View analysts' price targets for Soliton. Has Soliton been receiving favorable news coverage? News headlines about SOLY stock have trended negative on Saturday, InfoTrie reports. The research firm identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Soliton earned a media sentiment score of -2.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Soliton. Are investors shorting Soliton? Soliton saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 1,290,000 shares, an increase of 13.2% from the January 15th total of 1,140,000 shares. Based on an average daily trading volume, of 190,700 shares, the short-interest ratio is currently 6.8 days. Currently, 20.3% of the shares of the company are sold short. View Soliton's Short Interest. Who are some of Soliton's key competitors? Some companies that are related to Soliton include Repro Med Systems (KRMD), Alphatec (ATEC), Cytosorbents (CTSO), Repro-Med Systems (REPR), SeaSpine (SPNE), AngioDynamics (ANGO), RenovaCare (RCAR), Utah Medical Products (UTMD), Iradimed (IRMD), Accuray (ARAY), Repare Therapeutics (PYPD), iCAD (ICAD), Pulse Biosciences (PLSE), T2 Biosystems (TTOO) and Westaim (WEDXF). View all competitors. What other stocks do shareholders of Soliton own? Based on aggregate information from My MarketBeat watchlists, some companies that other Soliton investors own include Cronos Group (CRON), NVIDIA (NVDA), Canopy Growth (CGC), Square (SQ), AbbVie (ABBV), Aurora Cannabis (ACB), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA) and Verizon Communications (VZ). Who are Soliton's key executives? Soliton's management team includes the following people: Mr. Walter V. Klemp, Founder & Exec. Chairman (Age 59)Dr. Christopher C. Capelli, CEO, Pres, Chief Science Officer & Director (Age 59)Ms. Lori H. Bisson, CFO & Sec. (Age 48)Mr. Joe D. Tanner, Chief Operating Officer (Age 72)Mr. Lee Stranathan, Chief Marketing Officer What is Soliton's stock symbol? Soliton trades on the NASDAQ under the ticker symbol "SOLY." Who are Soliton's major shareholders? Soliton's stock is owned by a number of institutional and retail investors. Top institutional investors include Monashee Investment Management LLC (1.77%), Luminus Management LLC (0.78%), Sabby Management LLC (0.61%), First Republic Investment Management Inc. (0.57%), Matisse Capital (0.12%) and Bank of New York Mellon Corp (0.11%). View institutional ownership trends for Soliton. Which institutional investors are buying Soliton stock? SOLY stock was purchased by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Luminus Management LLC, Sabby Management LLC, First Republic Investment Management Inc., Virtu Financial LLC, Matisse Capital, and Bank of New York Mellon Corp. View insider buying and selling activity for Soliton. How do I buy shares of Soliton? Shares of SOLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Soliton's stock price today? One share of SOLY stock can currently be purchased for approximately $7.22. How big of a company is Soliton? Soliton has a market capitalization of $152.99 million. The company earns $-13,750,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis. Soliton employs 7 workers across the globe. What is Soliton's official website? The official website for Soliton is www.soliton.com. How can I contact Soliton? Soliton's mailing address is 5304 ASHBROOK DRIVE, HOUSTON TX, 77081. The company can be reached via phone at 844-705-4866. This page was last updated on 8/15/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
